• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunitybio Inc (NQ: IBRX )

    5.248 -0.192 (-3.52%)
    Streaming Delayed Price Updated: 1:45 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Immunitybio Inc

    < Previous 1 2 3 4 5 6 Next >
    PROCEPT BioRobotics Posts Strong Q3 Earnings, Joins Monte Rosa Therapeutics, EyePoint Pharmaceuticals And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Why LENZ Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
    These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
    Via Benzinga
    Topics Government
    Exposures Political
    Top 2 Health Care Stocks That May Fall Off A Cliff This Month
    Via Benzinga
    How Is The Market Feeling About ImmunityBio?
    Via Benzinga
    Jeff Bezos Ends Washington Post's 36-Year Tradition Of Endorsements, Leaving Staff 'Roiled'
    The Washington Post is not endorsing a candidate in a presidential election for the first time since 1988. Sources say the decision came from Jeff Bezos. 
    Via Benzinga
    Booz Allen Posts Upbeat Q3 Earnings, Joins Deckers Outdoor, Saia, Boyd Gaming And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Why Deckers Outdoor Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
    EF Hutton rates ImmunityBio (IBRX) as a Buy with a $30 target. Anktiva shows promise in cancer treatment, boosting response rates and survival outcomes. 
    Via Benzinga
    Texas Instruments Posts Strong Q3 Results, Joins Valmont Industries, Lithia Motors, Teledyne Technologies And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Why Champions Oncology Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Top 3 Health Care Stocks That Are Set To Fly This Quarter
    Via Benzinga
    9 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    IBRX Stock Earnings: ImmunityBio Misses EPS, Misses Revenue for Q2 2024
    IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
    Via InvestorPlace
    7 Biotech Stocks to Keep on Your Clinical Radar
    Biotech stocks have always been relevant. However, with the latest shift in the political race, this sector is bound to grab more eyeballs. 
    Via InvestorPlace
    3 Top Cancer Treatment Stocks to Buy Now
    These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
    Via InvestorPlace
    China's Bilibili And Ollie's Bargain Outlet Were Among 10 Mid Cap Stocks With Biggest Gains In The Last Week (June 16-June 22, 2024): Are They In Your Portfolio?
    Top performing mid-cap stocks last week: BILI (+23%), IBRX (+22%), SSL (+20%), OLLI (+15%), ITCI (+13%), AMKR (+12%), IRTC (+11%), RKLB (+11%), BFH (+10%), BRFS (+10%). 
    Via Benzinga
    Why ImmunityBio Stock Is Trading Higher Thursday
    The company announced insurance coverage of ANKTIVA, a immunotherapy used to treat non-muscle invasive bladder cancer that was unresponsive to other specific treatments. 
    Via Benzinga
    KB Home Reports Upbeat Earnings, Joins Harrow, Accenture, Gilead Sciences And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    3 Short-Squeeze Stocks Outwitting the Pessimistic Predictions
    Don't be discouraged by the bears. Here are my three picks of short-squeeze stocks to buy for investors everywhere. 
    Via InvestorPlace
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    These 3 Interesting Stocks Are Seeing Heavy Short Interest In June 2024
    Economic slowdown meets short-selling speculations. Candidates for incoming market volatility are here. 
    Via Talk Markets
    Amid Biotech Pitfalls, ImmunityBio Has Outperformed NVDA In The Last 3 Months
    In the last three months, IBRX outperformed NVDA by over 3x. 
    Via Talk Markets
    IBRX Stock Earnings: ImmunityBio Misses EPS, Beats Revenue for Q1 2024
    IBRX stock results show that ImmunityBio missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    The 3 Best Bargain Stocks to Buy in May 2024
    There are several types of bargain stocks for investors to consider. Here are the three best bargain stocks to buy now. 
    Via InvestorPlace
    Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.